Immix Biopharma Inc IMMX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 04/26/24 EDT
2.13quote price arrow up+0.03 (+1.43%)
Volume
84,502
52 week range
1.40 - 7.75
Loading...
  • Open2.08
  • Day High2.25
  • Day Low2.05
  • Prev Close2.10
  • 52 Week High7.75
  • 52 Week High Date12/18/23
  • 52 Week Low1.40
  • 52 Week Low Date05/26/23

Key Stats

  • Market Cap56.224M
  • Shares Out26.40M
  • 10 Day Average Volume0.17M
  • Dividend-
  • Dividend Yield-
  • Beta0.05
  • YTD % Change-69.22

KEY STATS

  • Open2.08
  • Day High2.25
  • Day Low2.05
  • Prev Close2.10
  • 52 Week High7.75
  • 52 Week High Date12/18/23
  • 52 Week Low1.40
  • 52 Week Low Date05/26/23
  • Market Cap56.224M
  • Shares Out26.40M
  • 10 Day Average Volume0.17M
  • Dividend-
  • Dividend Yield-
  • Beta0.05
  • YTD % Change-69.22

RATIOS/PROFITABILITY

  • EPS (TTM)-0.88
  • P/E (TTM)-2.42
  • Fwd P/E (NTM)-2.37
  • EBITDA (TTM)-16.136M
  • ROE (TTM)-104.35%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/11/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Immix Biopharma Inc

 

Profile

MORE
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue...
Ilya Rachman M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Gabriel Morris
Chief Financial Officer, Director
Address
11400 West Olympic Blvd., Suite 200
Los Angeles, CA
90064
United States

Top Peers

SYMBOLLASTCHG%CHG
RPHM
Reneo Pharmaceuticals Inc
1.67+0.02+1.21%
LTRN
Lantern Pharma Inc
5.50+0.04+0.73%
AVRO
AVROBIO Inc
1.21+0.02+2.11%
IMRX
Immuneering Corp
1.47+0.04+2.80%
GANX
Gain Therapeutics Inc
3.03-0.04-1.30%